MedTrace Logo

CTC in Lung Caner Patients With Bone Metastases

NCT04568291 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2021-08-12

No results posted yet for this study

Summary

1. Evaluate the feasibility of single cell sequencing technology based on three-dimensional bionic capture network;
2. To build a risk prediction model of bone related events based on single cell sequencing;
3. To verify the risk prediction model of bone related events by single cell sequencing;
4. To verify the comprehensive treatment of non-small cell lung cancer ( NSCLC) bone metastases.

Conditions

Interventions

OTHER

model treatment

the treatment decisions were decided by Machine Learning （ML） model in model treatment group

OTHER

routine treatment

the treatment decisions were decided by multi-disciplinary team （MDT）

Sponsors & Collaborators

  • Shanghai 6th People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2022-03-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04568291 on ClinicalTrials.gov